Terms: = Skin cancer AND LDH AND Diagnosis
116 results:
1. Characteristics of long-survivor metastatic melanoma after polychemotherapy and interferon: a retrospective study.
Py C; De Vito C; Tsantoulis P; Kaya G; Labidi-Galy SI; Dietrich PY
Swiss Med Wkly; 2023 Dec; 153():3504. PubMed ID: 38579317
[TBL] [Abstract] [Full Text] [Related]
2. Size selection of intrahepatic lesions for cryoablation contributes to abscopal effect and long-term survival in patients with liver metastatic melanoma receiving PD-1 blockade therapy.
Shen L; Tan H; Nie J; Jiang Y; Nuerhashi G; Qi H; Cao F; Wen C; Chen S; Zhang T; Zheng W; Liu P; Liu Y; Huang T; Li D; Zhang X; Fan W
Cancer Immunol Immunother; 2024 Mar; 73(4):68. PubMed ID: 38430269
[TBL] [Abstract] [Full Text] [Related]
3. A single-center retrospective analysis of prognoses in patients with melanoma brain metastases and effectiveness of treatment in Japan.
Wada S; Ogata D; Kashihara T; Okuma K; Eto H; Nakano E; Takahashi A; Namikawa K; Igaki H; Yamazaki N
Cancer Med; 2023 Dec; 12(24):21933-21943. PubMed ID: 38083908
[TBL] [Abstract] [Full Text] [Related]
4. Systemic therapy timing and use in patients with advanced melanoma at the end of life: A retrospective cohort study.
van Lith PEA; Schreuder K; Jalving M; Reyners AKL; Been LB; Rácz E; Fransen HP; Louwman MWJ
J Dermatol; 2024 Apr; 51(4):584-591. PubMed ID: 38078557
[TBL] [Abstract] [Full Text] [Related]
5. Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis.
Piulats JM; Watkins C; Costa-García M; Del Carpio L; Piperno-Neumann S; Rutkowski P; Hassel JC; Espinosa E; de la Cruz-Merino L; Ochsenreither S; Shoushtari AN; Orloff M; Salama AKS; Goodall HM; Baurain JF; Nathan P
Ann Oncol; 2024 Mar; 35(3):317-326. PubMed ID: 38048850
[TBL] [Abstract] [Full Text] [Related]
6.
Huang X; Chen L; Sha T; Lin Y; Zeng R; Xu J; Chen S; Cai HH; Zhang J; Zhou H; Sun PH; Jiang X
ACS Nano; 2023 Oct; 17(20):20073-20086. PubMed ID: 37792448
[TBL] [Abstract] [Full Text] [Related]
7. Assessing the prognostic value of IMDC risk score for nivolumab-treated patients with renal cancer and malignant melanoma.
Beypınar I; Sözel Y; Önder AH
Cancer Biomark; 2023; 38(3):367-377. PubMed ID: 37718781
[TBL] [Abstract] [Full Text] [Related]
8. Causes of Death in Cutaneous T-Cell Lymphoma Patients.
Lebas E; Collins P; Somja J; Nikkels AF
Dermatology; 2023; 239(6):860-867. PubMed ID: 37611553
[TBL] [Abstract] [Full Text] [Related]
9. Outcomes in patients with
Aglietta M; Chiarion-Sileni V; Fava P; Guidoboni M; Depenni R; Minisini A; Consoli F; Ascierto PA; Rinaldi G; Banzi M; Marconcini R; Gueli R; Ferraresi V; Tucci M; Tonini G; Lo Re G; Guida M; Del Vecchio M; Marcon IG; Queirolo P
Tumori; 2023 Dec; 109(6):537-545. PubMed ID: 37417313
[TBL] [Abstract] [Full Text] [Related]
10. CD30 expression in cutaneous B-cell lymphomas.
Afolayan-Oloye O; Zhao L; Tejasvi T; Chan MP; Harms PW; Fullen DR; Wilcox RA; Hristov AC
J Cutan Pathol; 2023 Sep; 50(9):819-827. PubMed ID: 37290910
[TBL] [Abstract] [Full Text] [Related]
11. Differences in glucose metabolic activity in liver metastasis separates two groups of metastatic uveal melanoma patients with different prognosis.
Del Carpio LP; Algarra MA; Sabaté-Llobera A; Rodriguez-Vida A; Rossi-Seoane S; Ruiz S; Leiva D; Ramos E; Lladò L; Lorenzo D; Gutierrez C; Cortes-Romera M; Caminal JM; Piulats JM
Cancer Med; 2023 Jul; 12(13):14062-14071. PubMed ID: 37211960
[TBL] [Abstract] [Full Text] [Related]
12. Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG.
Franklin C; Mohr P; Bluhm L; Meier F; Garzarolli M; Weichenthal M; Kähler K; Grimmelmann I; Gutzmer R; Utikal J; Terheyden P; Herbst R; Haferkamp S; Pfoehler C; Forschner A; Leiter U; Ziller F; Meiss F; Ulrich J; Kreuter A; Gebhardt C; Welzel J; Schilling B; Kaatz M; Scharfetter-Kochanek K; Dippel E; Nashan D; Sachse M; Weishaupt C; Löffler H; Gambichler T; Loquai C; Heinzerling L; Grabbe S; Debus D; Schley G; Hassel JC; Weyandt G; Trommer M; Lodde G; Placke JM; Zimmer L; Livingstone E; Becker JC; Horn S; Schadendorf D; Ugurel S
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37028819
[TBL] [Abstract] [Full Text] [Related]
13. Staging lymph nodes and blood at diagnosis in mycosis fungoides identifies patients at increased risk of progression to advanced stage: A retrospective cohort study.
Allen PB; McCook-Veal AA; Switchenko JM; Paulino DM; Niyogusaba T; Baird KM; Tarabadkar ES; Lechowicz MJ
Cancer; 2023 Feb; 129(4):541-550. PubMed ID: 36523150
[TBL] [Abstract] [Full Text] [Related]
14. Changes in outcomes and factors associated with survival in melanoma patients with brain metastases.
Hasanov M; Milton DR; Davies AB; Sirmans E; Saberian C; Posada EL; Opusunju S; Gershenwald JE; Torres-Cabala CA; Burton EM; Colen RR; Huse JT; Glitza Oliva IC; Chung C; McAleer MF; McGovern SL; Yeboa DN; Kim BYS; Prabhu SS; McCutcheon IE; Weinberg JS; Lang FF; Tawbi HA; Li J; Haydu LE; Davies MA; Ferguson SD
Neuro Oncol; 2023 Jul; 25(7):1310-1320. PubMed ID: 36510640
[TBL] [Abstract] [Full Text] [Related]
15. Identification of a miRNA-based non-invasive predictive biomarker of response to target therapy in BRAF-mutant melanoma.
Ruggiero CF; Fattore L; Terrenato I; Sperati F; Salvati V; Madonna G; Capone M; Valenti F; Di Martino S; Mandoj C; Liguoro D; Castaldo V; Cafaro G; Simeone E; Vanella V; Russillo M; Conti L; Cuda G; Giannarelli D; Ascierto PA; Mancini R; Ciliberto G
Theranostics; 2022; 12(17):7420-7430. PubMed ID: 36438490
[No Abstract] [Full Text] [Related]
16. Predictors of large cell transformation in patients with Sezary Syndrome-A retrospective analysis.
Jairath NK; Bardhi R; Runge JS; Bledea R; Jairath R; Wang Y; Patrick M; Wilcox RA; Hristov AC; Tsoi LC; Tejasvi T
PLoS One; 2022; 17(11):e0277655. PubMed ID: 36383618
[TBL] [Abstract] [Full Text] [Related]
17. High serum ldh and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy.
Dercle L; Ammari S; Roblin E; Bigorgne A; Champiat S; Taihi L; Plaian A; Hans S; Lakiss S; Tselikas L; Rouanne M; Deutsch E; Schwartz LH; Gönen M; Flynn J; Massard C; Soria JC; Robert C; Marabelle A
Eur J Cancer; 2022 Dec; 177():80-93. PubMed ID: 36332438
[TBL] [Abstract] [Full Text] [Related]
18. Chemotherapy induced juvenile dermatomyositis: a novel presentation- a case report.
Vagha K; Akhil CVS; Madirala S; Varma A; Lakra M; Vagha J
BMC Pediatr; 2022 Oct; 22(1):623. PubMed ID: 36316673
[TBL] [Abstract] [Full Text] [Related]
19. A distinct four-value blood signature of pyrexia under combination therapy of malignant melanoma with dabrafenib and trametinib evidenced by an algorithm-defined pyrexia score.
Schaefer H; Rübben A; Esser A; Araujo A; Persa OD; Leijs M
PLoS One; 2022; 17(8):e0273478. PubMed ID: 36006943
[TBL] [Abstract] [Full Text] [Related]
20. Immune checkpoint inhibitors-associated thrombosis in patients with lung cancer and melanoma: a study of the Spanish society of medical oncology (SEOM) thrombosis and cancer group.
Cánovas MS; Garay DF; Moran LO; Pérez JR; Rubio CMG; de Mena ML; Portero BO; Castro JB; Lage Y; Lavin DC; Blanco ABR; de Soignie AMMF; Perejón JZB; Colomo LJ; Boluda NB; Moreno JB; Verduguez TQ; Garrido CR; Huertas RM; Puig CFI; Martín AJM
Clin Transl Oncol; 2022 Oct; 24(10):2010-2020. PubMed ID: 35668339
[TBL] [Abstract] [Full Text] [Related]
[Next]